Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:27:40.112Z.
Calculation as of: 2026-10-06T21:27:40.112Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 82cee4a6010f8650e239c44e6fa86f6cad5a1cacb0b867e980d6d40a64789328
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Nautilus Biotechnolgy, Inc.
Market Cap
$225.24M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$231.37M
EV/EBIT Ratio
N/A
TTM Avg
378.61x
3Y Avg
334476.42x
5Y Avg
334476.42x
Market Cap
$231.77M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$218.30M
EV/EBIT Ratio
N/A
TTM Avg
1.44x
3Y Avg
1.44x
5Y Avg
1.44x
Market Cap
$216.91M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nautilus Biotechnolgy, Inc. (NAUT) | $225.24M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $227.60M | N/A | N/A | N/A | N/A |
| Vogenx Inc. (VOGX)vs › | $227.91M | N/A | N/A | N/A | N/A |
| Profound Medical Corp. (PROF)vs › | $220.93M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $231.37M | N/A | 378.61x | 334476.42x | 334476.42x |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $231.77M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | N/A | 1.44x | 1.44x | 1.44x |
| InflaRx N.V. (IFRX)vs › | $232.72M | N/A | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | N/A | N/A | N/A | N/A |
| Utah Medical Products, Inc. (UTMD)vs › | $235.08M | 22.90x | 12.07x | 10.11x | 11.81x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
